Interplay between SOX9, β-catenin and PPARγ activation in colorectal cancer  by Panza, Anna et al.
Biochimica et Biophysica Acta 1833 (2013) 1853–1865
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrInterplay between SOX9, β-catenin and PPARγ activation in
colorectal cancerAnna Panza a,1, Valerio Pazienza a,1, Maria Ripoli a, Giorgia Benegiamo a, Annamaria Gentile a,
Maria Rosaria Valvano a, Bartolomeo Augello b, Giuseppe Merla b, Clelia Prattichizzo c, Francesca Tavano d,
Elena Ranieri c, Pierluigi di Sebastiano d, Manlio Vinciguerra e, Angelo Andriulli a,
Gianluigi Mazzoccoli f,⁎,1, Ada Piepoli a,⁎⁎,1
a Department of Medical Sciences, Division and Laboratory of Gastroenterology, IRCCS Scientiﬁc Institute and Regional General Hospital “Casa Sollievo della Sofferenza”,
Opera di Padre Pio da Pietrelcina San Giovanni Rotondo (FG), Italy
b Medical Genetics Unit, IRCCS Scientiﬁc Institute and Regional General Hospital “Casa Sollievo della Sofferenza”, Opera di Padre Pio da Pietrelcina San Giovanni Rotondo (FG), Italy
c Department of Medical Science and Surgery, University of Foggia, Italy
d Department of Surgery, IRCCS Scientiﬁc Institute and Regional General Hospital “Casa Sollievo della Sofferenza”, Opera di Padre Pio da Pietrelcina San Giovanni Rotondo (FG), Italy
e University College London, Institute for Liver and Digestive Health, Division of Medicine, Royal Free Campus, London, UK
f Department of Medical Sciences, Division of Internal Medicine and Chronobiology Unit, IRCCS Scientiﬁc Institute and Regional General Hospital “Casa Sollievo della Sofferenza”,
Opera di Padre Pio da Pietrelcina San Giovanni Rotondo (FG), Italy⁎ Correspondence to: G. Mazzoccoli, Department of Med
Medicine and Chronobiology Unit, IRCCS Scientiﬁc Institut
“Casa Sollievo della Sofferenza”, Opera di Padre Pio da P
71013, San Giovanni Rotondo (FG), Italy. Tel.:+39 0 882 8
⁎⁎ Correspondence to: A. Piepoli, Department ofMedical S
of Gastroenterology, IRCCS Scientiﬁc Institute and Regional
della Sofferenza”, Opera di Padre Pio da Pietrelcina, Vi
Giovanni Rotondo (FG), Italy. Tel.:+39 0 882 416281; fax:
E-mail addresses: g.mazzoccoli@operapadrepio.it (G
a.piepoli@operapadrepio.it (A. Piepoli).
1 These authors have contributed equally.
0167-4889/$ – see front matter © 2013 Elsevier B.V. All
http://dx.doi.org/10.1016/j.bbamcr.2013.04.004a b s t r a c ta r t i c l e i n f oArticle history:
Received 23 July 2012
Received in revised form 3 April 2013
Accepted 5 April 2013






Colon cancer cell linesColorectal carcinogenesis relies on loss of homeostasic mechanisms regulating cell proliferation, differentia-
tion and survival. These cell processes have been reported to be inﬂuenced independently by transcription
factors activated downstream of the Wnt pathway, such as SOX9 and β-catenin, and by the nuclear receptor
PPARγ. The purpose of this study was to explore the expression levels and functional link between SOX9,
β-catenin and PPARγ in the pathogenesis of colorectal cancer (CRC). We evaluated SOX9, β-catenin and
PPARγ expression levels on human CRC specimens by qPCR and immunoblot detection. We tested the hy-
pothesis that PPARγ activation might affect SOX9 and β-catenin expression using four colon cancer cell
lines (CaCo2, SW480, HCT116, and HT29 cells). In CRC tissues SOX9 resulted up-regulated at both mRNA
and protein levels when compared to matched normal mucosa, β-catenin resulted up-regulated at protein
levels, while PPARGmRNA and PPARγ protein levels were down-regulated. A signiﬁcant relationship was ob-
served between high PPARG and SOX9 expression levels in the tumor tissue and female gender (p = 0.005
and p = 0.04, respectively), and between high SOX9 expression in the tumor tissue and age (p = 0.04)
and microsatellite instability (MSI), in particular with MSI-H (p = 0.0002). Moreover, treatment with the
synthetic PPARγ ligand rosiglitazone induced different changes of SOX9 and β-catenin expression and
subcellular localization in the colon cancer cell lines examined. In conclusion, SOX9, β-catenin and PPARγ ex-
pression levels are deregulated in the CRC tissue, and in colon cancer cell lines ligand-dependent PPARγ ac-
tivation unevenly inﬂuences SOX9 and β-catenin expression and subcellular localization, suggesting a
variable mechanistic role in colon carcinogenesis.
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Colorectal cancer (CRC) is one of the most common malignancies
in developed countries and a major cause of cancer-related death
worldwide [1]. Presently, the ﬁrst-choice treatment is surgical exci-
sion with or without adjuvant chemotherapy [2], but the identiﬁca-
tion of novel biomarkers for prognosis and molecular targets for
therapeutic intervention is ﬁrmly needed. CRC onset and progression
are linked to mutational pathways, such as chromosomal instability
(CIN) and microsatellite instability (MSI) [3], and colorectal carcino-
genesis is related to the progressive loss of homeostatic control of
cell proliferation, differentiation and apoptosis [4]. The transcription
factors play a key role in the regulation of these cell processes. An
Table 1
Clinical and pathological features of colorectal cancer patients.
n = 31 %
Age (years)



































a Caecum, ascending colon, proximal transverse.
b Distal transverse, descending colon, sigmoid colon and rectum.
1854 A. Panza et al. / Biochimica et Biophysica Acta 1833 (2013) 1853–1865emerging role is attributed to SOX [sex-determining region Y (Sry)
box-containing], member of a transcription factor family with homol-
ogy in their 79-amino acid DNA-binding domain known as the HMG
box. SOX family is involved in the control of stem cell maintenance
and cell phenotype choice during embryonic development and commit-
ted differentiation in multiple organ systems [4]. In particular, SOX9 is
considered an important regulator of cell fate and differentiation and
is implicated in the maintenance of a non differentiated population of
putative stem/progenitor cells for adult tissue renewal in intestinal
epithelium, critical for maintaining constant integrity of epithelial
barriers [5]. In the colon, SOX9 is localized to the proliferative compart-
ment of the intestinal epithelium and is involved downstream in the
Wnt/β-catenin signaling for the management of epithelium homeosta-
sis [4,6,7]. Aberrant proliferation of tissue-speciﬁc stem cells is im-
plicated in gastrointestinal tumorigenesis, and SOX9 has been found
deregulated in many types of cancer [8–11] including those of the di-
gestive system and in particular in colorectal cancer [4].
The key effector protein in Wnt pathway is the transcription acti-
vator β-catenin, whose coding gene (CTNNB1) can function as an on-
cogene involved in tumor cell phenotype onset [12,13]. Cytoplasmic
β-catenin forms a complex with APC (adenomatous polyposis coli),
the associated protein Axin/Conductin, protein kinases such as casein
kinase (CK) and glycogen synthase kinase-3β (GSK-3β), which phos-
phorylate β-catenin and other elements of the molecular proteolytic
complex. Phosphorylated (p) β-catenin is an ephemeral, transcrip-
tionally inactive mediator, whose half life is settled on by the closely
controlled equilibrium between phosphorylation, dephosphorylation,
ubiquitination, proteasomal degradation and subcellular localization.
β-catenin translocates from the cytoplasm to the nucleus and inter-
acts with the TCF/LEF1 family transcription factors, inducing the ex-
pression of target-genes such as MYC and CCND1[13,14]. β-catenin
is also involved in cell adhesion, bridging between cadherins and
the actin cytoskeleton at the cell–cell adherens junctions. Deregula-
tion of β-catenin levels, partly caused by mutations of the APC gene,
is thought to play a role in the development of colorectal cancer
[15]. In over 80% of human colon cancers occur mutations in APC,
which determine large deletions in the C-terminus of the protein [16].
Another important cell fate regulator is represented by PPARγ
(Peroxisome Proliferator-Activated Receptor γ), a ligand-activated
transcription factor belonging to the large superfamily of nuclear recep-
tors. PPARγ is known to regulate cellular proliferation/differentiation,
and could be involved in gastrointestinal cancerogenesis [17–20].
High levels of PPARγ expression are measured in the normal mucosa
of colon and rectum [21], and enhanced tumorigenicity in mouse
small intestine and colon has been found associated with decreased in-
testinal PPARγ levels [22]. Accordingly, in a number of colorectal cancer
patients decreased PPARγ expression levels have been found compared
with adjacent normal colonic mucosa [23]. On the other hand, in a large
series of primary colorectal cancersmore than half of tumorswere char-
acterized by PPARγ overexpression when compared to the matched
normal mucosa [24], but with a signiﬁcant association between PPARγ
downregulation, occurrence of distant metastases and poorer overall
patients' survival [25,26]. The biomolecular events involved are not
yet clear, but PPARγ deregulation probably plays different and context
dependent roles in CRC onset and progression. Recently the effects
of PPARγ activity on gastrointestinal tract tumor biology have been
pinpointed by studies exploring genetic mechanisms to assess the
role of PPARγ as a tumor suppressor and inducer of differentiation of
cancer stem cells, and evaluating the clinical applications and potential
therapeutic employ of PPARγ agonists in colorectal cancer treatment
[24,27–29].
PPARγ is able to maintain lower steady-state levels of β-catenin in
the presence of a normal APC pathway, and ligand related PPARγ ac-
tivation decreases β-catenin levels [30].
Based on these premises, considering the effects of PPARγ ligands
on cell fate and its direct interaction on β-catenin [31,32], and the roleof Wnt/β-catenin target-gene SOX9 in colorectal cancer onset and
progression [4,7,8], we hypothesized that the interaction between
PPARγ activation and SOX9 expression may play a role via β-catenin
signaling in colorectal cancerogenesis. To address this hypothesis,
we have investigated PPARγ, SOX9 and β-catenin expression levels
in human colorectal cancer specimens, evaluating their relationships
to clinical and pathological features, and assessed the effects of
PPARγ activation on SOX9 and β-catenin expression in vitro in colon
cancer cell lines.2. Materials and methods
2.1. Patients and tissue specimens
We analyzed primary tumors and matched normal specimens from
a cohort of 31 CRC patients undergoing curative surgery at our Institu-
tion (21 men and 10 women, mean age ± SD 66 ± 13 years). Clinical
and pathological features of colorectal cancer patients are shown in
Table 1. Tissue specimens, collected according to the guidelines of the
local Ethical Committee, were immediately frozen in liquid nitrogen
and stored at−80 °C until nucleic acid and protein extraction. Written
informed consent was obtained from each patient in accordance with
the Institutional guidelines.
Our investigation has been conducted in accordance with the eth-
ical standards and the Declaration of Helsinki, and according to the
national and international guidelines, after approval of our Institu-
tional Review Board.
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CaCo2, SW480, HCT116, and HT29 cells were cultured at 37 °C in
5% CO2 atmosphere in DMEM and MEM Alpha media, supplemented
with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 ng/ml
streptomycin (Invitrogen Life Technologies, Milan Italy).
The synthetic rosiglitazone (Ros) ligand was used to determine
PPARγ activation. The cells were treated with vehicle (ethanol) or
20 μM Ros for 24 h.2.3. Antibodies and chemicals
Rabbit polyclonal antibodies directed against β-catenin and
PPARγ were purchased from Cell Signaling Technology (Euroclone,
Milan, Italy). Mouse antibodies directed against β-actin and rabbit
polyclonal antibodies directed against SOX9 were purchased from
Santa Cruz (D.B.A., Milan, Italy). Rosiglitazone was purchased from
Cayman Chemical Company (Ann Arbor, Michigan, USA).2.4. Quantitative real time PCR (qPCR)
Total RNA was extracted from tissue samples and from CaCo2,
SW480, HCT116, and HT29 cells upon treatment with rosiglitazone
using the RNeasy® Mini Kit (QIAGEN S.r.l., Milan, Italy), and subse-
quently digested by DNase I. cDNA was synthesized from 500 ng
total RNA with High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA, USA) and random hexanucleotides.
For qPCR, we used the following SYBR Green Quantitect Primers pur-
chased from Qiagen: human SOX9 (QT00001498), human CTNNB1
(QT00077882), human PPARG (QT00029841). Reactions were set up in
96-well plates using a 7700 RT-PCR System (Applied Biosystems, Foster
City, CA, USA) and all samples were assayed in triplicate. The data were
analyzed using the default and variable parameters available in the SDS
software package (version 1.9.1; Applied Biosystems, Foster City, CA,
USA). Target gene expression levels were normalized using the GAPDH
housekeeping control and themRNA amount of each target gene relative
toGAPDHwas calculated through the comparative Ctmethod, also called
the 2(−ΔΔCt) method.2.5. Immunoblot detection
Total proteinswere extracted from5 snap frozen CRC specimens ho-
mogenized through mechanical and detergent based lysis, Ripa buffer
(150 mM NaCl, 50 mM TRIS–HCl pH 7.4, 0.1% sodium dodecyl sulfate
(SDS), 1% Triton, 5 mM ethylenediaminetetraacetic acid (EDTA) and
1% cholic acid sodium salt), supplemented with protease inhibitor
cocktail (COMPLETE; Roche Diagnostics, Mannheim, Germany), 1 mM
phenylmethanesulphonylﬂuoride and 1 mM sodium orthovanadate,
being used as detergent. After boiling at 100 °C for 3 min, equal
amounts of proteins were loaded on 10% polyacrylamide gels and
separated by electrophoresis. Protein transfer was performed on PVDF
membrane (Millipore S.p.A., Milan, Italy). The membranes were
blocked with 5% skim milk in wash buffer (20 mM Tris–HCl, pH 7.6,
140 mMNaCl, 0.1% Tween 20) and incubated with the speciﬁc primary
antibodies diluted in blocking solution, at appropriate dilutions. Follow-
ing three washes, membranes were incubated with a secondary goat
anti-mouse or goat anti-rabbit horseradish peroxydase-conjugated an-
tibody (BioRad, Hercules, CA, USA) diluted 1:3000 in wash buffer. After
three further washes, proteins were revealed by chemiluminescence
(ECL, Amersham Biosciences AB, Uppsala Sweden) and the signal
detected on an X-ray ﬁlm (Amersham Biosciences AB, Uppsala
Sweden). For quantitative measurement, the ﬁlm was scanned and the
spots corresponding to the proteins of interest were analyzed using the
image processing program ImageJ (NIH Image, Bethesda, MD).2.6. Indirect immunoﬂuorescence (IFL)
CaCo2, SW480, HCT116, and HT29 cells grown and transfected on
coverslips, were ﬁxed for 30 min in 4% paraformaldehyde at 4 °C.
Coverslips were then washed three times in PBS and incubated with
the β-catenin or SOX9 antibody diluted 1:100 in PBS, 2% bovine
serum albumin (BSA), 0.3% Triton X-100 for 2 h at room temperature
(RT). After three washes in PBS, cells were incubated 2 h at RT with
Alexa 488-labeled anti-rabbit antibodies diluted at 1:50. After rinsing
three times in PBS, coverslips were mounted on microscope slides.
For ﬂuorescence microscopy, slides mounted for immunoﬂuores-
cence were observed using a Nikon Eclipse E600 microscope.
2.7. Immunoprecipitation (IP)
Cells treatedwith 20 μMof rosiglitazone for 24 hwerewashedwith
PBS and lysed in 0.5 ml of RadioImmuno Precipitation (RIPA) buffer
(150 mMNaCl, 50 mMTris–HCL, 1%Nonidet P-40, 0.1% sodiumdodecyl
sulfate, 0.5% sodiumdeoxycholate, pH 8) for 60 min at 4 °C, centrifuged
and the supernatantwas collected. For immunoprecipitation (IP) assays
a protein G immunoprecipitation kit (Sigma-Aldrich, St. Louis, MO,
USA) was used and a pre-clearing step (Protein G Agarose suspension
and cell extract sample were incubated for 2 h at 4 °C) was carried
out to reduce background caused by non-speciﬁc adsorption of irrele-
vant cellular proteins to the Protein G Agarose. To 200 μg of the lysate
2.5 μg of mouse anti-β-Catenin antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) was added and left 3 h at 4 °C, followed by addi-
tion of 50 μl of beads suspension overnight at 4 °C. Beads were washed
two timeswith IP 1× buffer and ﬁve timeswith IP 0.1× buffer following
the speciﬁc protocol, and immunoprecipitated proteins were eluted by
boiling in 40 μl of 1× Laemmli buffer before being loaded onto a SDS
gel (10% acrylamide) and transferred to a Nitrocellulose membrane
(Bio-Rad Laboratories, Hercules, CA, USA) followed by immunoblot
analysis. The primary antibodies used were mouse anti-β-Catenin
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-PPARγ
(Cell Signaling Technology, Inc., Danvers, MA, USA) and rabbit
anti-SOX9 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies.
The secondary antibodies used were goat anti-mouse IgG HRP-linked
or goat anti-rabbit IgG HRP-linked antibodies (Santa Cruz Biotechnolo-
gy, Santa Cruz, CA, USA). Chromogenic development of the western
blots was obtained by using the Immun-Star Western C kit (Bio-Rad
Laboratories, Hercules, CA, USA).
2.8. MTT assays for cell viability and cell proliferation rate
Cell viability assays were carried out in CaCo2, SW480, HCT116,
and HT29 cell lines. Cells were plated (1 × 105 cells/well) in quadru-
plicate onto a 12-well cultured plate, and treated with 20 μM of
rosiglitazone for 24 h. On 24, 48, 72 and 96 h the cells were harvested
by trypsinization and the reduction in cell viability was determined
using the MTT assay. Cell viability was expressed as optical density
(OD), which was detected using a NANODrop reader at 570 nm.
The results are expressed as the mean of adsorbances from quadrupli-
cate samples. Two independent experiments were carried out and
the results were expressed based on the following formula: cell
viability% = number of cells in drug treatment group / number of
cells in control group × 100%.
To evaluate the anti-proliferative effect of rosiglitazone the
four cell lines were plated onto 96-well plates at approximately
2 × 104 cells/well and treated with increasing concentrations (10,
20, 40 and 60 μM) of rosiglitazone for 48 h. Then MTT reagent was
added and the absorbance at 570 nm was recorded using an
enzyme-linked immunosorbent assay (ELISA) reader. The prolifera-
tion inhibition rate (IR) was calculated according to the following
formula: IR% = [1 − absorbance of drug treatment group / absorbance
of vehicle control group] × 100%.
Fig. 1. SOX9, PPARG and CTNNB1mRNA expression evaluated by qPCR. SOX9, PPARG and
CTNNB1 mRNA expression in 31 CRC specimens (T) paired to normal tissues (N) eval-
uated by qPCR. Outliers are indicated by asterisk (*) or circle (°) where appropriate.
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To evaluate the effect of PPARγ activation on the cell cycle, the
CaCo2, SW480, HCT116, and HT29 cell lines were treated with
20 μM of rosiglitazone for 24 h or 48 h, collected by centrifugation
permeabilized with ice-cold 70% ethanol for at least 1 h and washed
with PBS. The cells were then treated with RNase A at 37 °C for
30 min and resuspended in PBS containing 20 μg/ml propidium
iodide and stained at 4 °C for 30 min. The DNA contents were then
analyzed by EPICS ALTRA (Beckman Coulter, Inc.).
2.10. Microsatellite instability
The microsatellite instability (MSI) analysis was performed using
the Bethesda panel of microsatellite (BAT25, BAT26, D5S346,
D17S250 and D2S123) evaluated by means of a multiplex-PCR and
PAGE analysis. Tumors showing instability in four or more markers
were classiﬁed as high MSI (MSI-H), those showing it in two markers
as low MSI (MSI-L), and those showing no instability as microsatellite-
stable (MSS).
2.11. Statistical analysis
SOX9, PPARG and CTNNB1mRNA expression levels of CRC tissue
were compared with those of adjacent normal mucosa, calculated
using the formula 2−ΔΔCt and values were reported as median, 25th
percentile (ﬁrst quartile, Q1) and 75th percentile (third quartile,
Q3). For continuous variables, normal distribution was veriﬁed by
the Shapiro–Wilk test and the one-sample Kolmogorov–Smirnov
test. For normally distributed variables, hypotheses regarding differ-
ences among the groups were compared by means of the paired
t-test, Student's t-test or by means of the analysis of variance
(ANOVA) as indicated. For non-normally distributed variables, hy-
potheses regarding differences among the groups were compared
by means of a non-parametric Wilcoxon signed rank sum test, the
Mann–Whitney rank sum test or the Kruskal–Wallis rank sum test
as indicated. Statistical analyses were also performed on the subjects
divided into quartile groups and by using Pearson's chi-square test to
evaluate interactions between variables. P-values b0.05 were consid-
ered statistically signiﬁcant. Survival rates were calculated by the
Kaplan–Meier method for analysis of censored data. All analyses
were performed using SPSS Statistical Package (SPSS v17, Chicago,
IL, US). For protein expression levels and in vitro experiments, the re-
sults are expressed as means ± SE.
3. Results
3.1. SOX9, β-Catenin, PPARG expression levels in tumoral tissue
specimens matched to normal mucosa
We previously reported deregulated SOX9, CTNNB1 and PPARG
mRNA levels in CRC tissue, evaluated by microarray analysis
(ArrayExpress accession n. E-MTAB-57) [33]. As an initial step, we
sought to corroborate these data, on 31 pairs of tumor tissue/normal
mucosa from 28well–moderately differentiated (G1–G2) colorectal tu-
mors and from 3 poorly differentiated–undifferentiated (G3–G4) colo-
rectal tumors, resected from 21 male and 10 female patients (mean
age ± SD 66 ± 13 years). Clinical and pathological features of colorec-
tal cancer patients are shown in Table 1. Using qPCR, in tumor tissue
compared to matched normal tissue was observed SOX9 up-regulation
(median = 1.73, Q1–Q3 = 0.62–2.86, p = 0.004) and PPARG down-
regulation (median = 0.41, Q1–Q3 = 0.23–0.70, p = 0.0005). No sta-
tistically signiﬁcant differencewas observed in CTNNB1 expression levels
(median = 1.01, Q1–Q3 = 0.58–1.42, p = 0.984). Median values, 25th
and 75th percentile, and extremes of GAPDH-Ct value/target gene-Ct
value are shown in Fig. 1.When detected bywestern blot SOX9 and PPARγ protein expression
showed the same trend of RNA expression in tumors as compared to
normal tissue (Fig. 2, Panels A and B) while β-catenin expression
resulted in an increase only at the protein level, suggesting that a post
transcriptional mechanism may be involved.3.2. Relationship of gene expression levels to clinical–pathological
parameters in CRC patients
Associations between gene expression levels and clinical–
pathological features (age, gender, tumor site and stage, and MSI
status) of CRC patients are shown in Table 2. A statistically signiﬁcant
relationship was observed between higher PPARG and SOX9 expression
levels in the tumor tissue and female gender (p = 0.005 and p = 0.04,
respectively), and between high SOX9 expression in the tumor tissue
and age (p = 0.04) and MSI status, in particular with MSI-H (p =
0.0002) (Table 2).
Kaplan–Meier method for analysis of censored data showed no
statistically signiﬁcant decrease in survival for the patients with
high PPARG expression levels (P = 0.414), high SOX9 expression
levels (P = 0.437), or high CTNNB1 expression levels (P = 0.371)
(Fig. 3).3.3. Effect of rosiglitazone treatment on SOX9 and CTNNB1 expression
levels in colon cancer cell lines
Considering the role of Wnt/β-catenin target-gene SOX9 in colo-
rectal cancer onset and progression and the direct interaction of
PPARγ ligands on β-catenin, we tested the effect of treatment with
20 μM rosiglitazone, a PPARγ activator, on four colorectal cancer cell
lines. As shown in Fig. 4, after treatment a statistically signiﬁcant de-
crease was observed in SOX9 and CTNNB1mRNA expression in CaCo2
(FC = −1.47, p b 0.05 and FC = −1.50, p b 0.01, respectively) and
in HT-29 (FC = −2.88, p b 0.001 and FC = −2.55, p b 0.001, re-
spectively). In HCT116 we observed a statistically signiﬁcant increase
of SOX9 expression (FC = 1.95; p b 0.01). In SW480 rosiglitazone
treatment did not cause statistically signiﬁcant changes of SOX9 and
CTNNB1 expression. As a control for the modulation of PPARγ activity
by rosiglitazone, we examined whether this ligand increased the ex-
pression levels of fatty acid binding protein 1 (FABP1) or fatty acid
synthase (FAS), a well-established target of PPARγ activity (Fig. 4).
Fig. 2. Immunoblot detection of SOX9, β-catenin and PPARγ in proteins extracted from selected paired normal tissues and CRC specimens. Panel A: Western blot analysis reveals
up-regulated SOX9 and β-catenin expression in CRC tissue (T) compared to normal mucosa (N) in 5 different specimens. On the contrary an opposite trend was depicted for PPARγ
protein. Patient identiﬁcation numbers are displayed at the top of ﬁgure. Panel B: The plots represent the signal quantiﬁcation of the western blot experiments by densitometry of
SOX9, β-catenin and PPARγ normalized to β-actin expression as reference protein.
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colon cancer cells upon rosiglitazone treatment
We then performed immunoﬂuorescence staining for SOX9,
β-catenin, and PPARγ. Treated and untreated CaCo2 cells displayed
nuclear localization for SOX9 staining, and the main difference was
represented by decreased levels of SOX9 within nuclei in CaCo2
cells treated with rosiglitazone at a concentration of 20 μM (Fig. 5,
Panel e) as compared to vehicle treated cells (Fig. 5, Panel a). As
shown in Fig. 6, vehicle treated CaCo2 cells displayed classical
β-catenin localization around the cellular membrane and within the
nucleus (Fig. 6, Panel a). On the other hand, β-catenin protein was
not present within nuclei upon 24-hour treatment with rosiglitazoneTable 2
Clinicopathological parameters in CRC patients and relationship with gene expression level
CRC PPARγ
n = 31 Median Q1 Q3 p v
Age b62 11 0.50 0.23 1.02
62–74 12 0.44 0.26 0.61 0.8
>74 8 0.34 0.15 0.65
Gender M 21 0.28 0.14 0.53 0.0
F 10 0.72 0.41 1.02
Cancer location Proximal 16 0.53 0.77 0.30
Distal 15 0.25 0.13 0.59 0.0
Grading G1/G2 28 0.45 0.20 0.72
G3/G4 3 0.24 0.23 0.66 0.6
A 1 0.14 0.14 0.14
Dukes staging system B 11 0.32 0.14 0.56 0.1
C 19 0.53 0.25 0.80
D 0
Carcinoma in situ 5 0.53 0.49 0.74
Histologic type Adenocarcinoma 26 0.39 0.23 0.66 0.5
MSI-H 6 0.38 0.16 0.70
MSI status MS-L 6 0.44 0.28 0.59 0.9
MSS 17 0.41 0.25 0.74
Vascular invasion Yes 15 0.53 0.14 1.02
Not 16 0.40 0.25 0.54 0.6at a concentration of 20 μM (Fig. 6, Panel d). SW480 cells displayed
nuclear localization of SOX9, which was unaffected by rosiglitazone
(Fig. 5, Panels a and e). As for β-catenin, SW480 untreated cells
displayed plasma membrane but not nuclear localization (Fig. 6,
Panel a). Conversely, β-catenin protein was present within SW480
nuclei upon 24-hour treatment with rosiglitazone at a concentration
of 20 μM (Fig. 6, Panel d). No change was observed in the HCT116
cell line for both proteins upon treatment with 20 μM rosiglitazone
(Fig. 5, Panels a and e; Fig. 6, Panels a and d). In HT-29 cell line,
SOX9 staining displayed nuclear localization in rosiglitazone treated
and vehicle treated cells (Fig. 5, Panels a and e). Canonical β-catenin
localization around the cellular membrane, but not within nuclei,
was observed in vehicle treated cells (Fig. 6, Panel a) with an increases.
SOX9 CTNNB1
alues Median Q1 Q3 p values Median Q1 Q3 p values
2.21 1.76 3.76 0.70 0.58 1.51
4 1.21 0.53 1.76 0.04 1.06 0.62 1.61 0.70
0.80 0.48 3.19 1.06 0.63 1.20
05 1.07 0.55 1.87 0.70 0.51 1.25
2.37 1.69 4.52 0.04 1.13 0.90 1.51 0.29
1.86 1.17 3.33 1.10 0.64 1.61
7 1.07 0.44 1.87 0.11 0.86 0.49 1.22 0.11
1.70 0.58 2.88 1.06 0.58 1.47
3 2.21 1.69 2.64 0.46 0.70 0.63 0.86 0.42
0.80 0.80 0.80 0.32 0.32 0.32
6 1.36 0.27 3.76 0.50 0.86 0.37 1.18 0.12
1.84 0.98 2.64 1.11 0.63 1.51
1.07 0.55 1.67 1.22 1.08 1.42
8 1.81 0.68 2.89 0.24 0.95 0.58 1.25 0.48
5.59 2.89 6.87 0.61 0.49 0.90
4 2.25 1.87 2.86 0.0002 1.10 0.70 1.25 0.27
0.80 0.53 1.73 1.11 0.65 1.51
1.73 0.68 2.86 1.08 0.49 1.59
5 1.61 0.58 2.76 1.00 0.95 0.62 1.20 0.57
Fig. 3. Cumulative survival of patient subdivided into quartile groups according to PPARG expression, SOX9 expression and CTNNB1 expression. No statistically signiﬁcant difference
was found in cumulative survival rates of the patients divided into quartile groups. Q1 = lower quartile and Q3 = upper quartile.
1858 A. Panza et al. / Biochimica et Biophysica Acta 1833 (2013) 1853–1865in cell–cell junction localization upon 24-hour treatment with
rosiglitazone at a concentration of 20 μM (Fig. 6, Panel d). No change
was observed in all cell lines for PPARγ protein upon treatment with
20 μM rosiglitazone (Fig. 7, Panels a–d).
3.5. Immunoprecipitation (IP) of SOX9, β-Catenin and PPARγ in colon
cancer cells upon rosiglitazone treatment
In order to assess whether the interaction among SOX9, β-Catenin
and PPARγwas direct or indirect, an immunoprecipitation experiment
was performed upon treatment with rosiglitazone at a concentrationFig. 4. SOX9 and CTNNB1 mRNAs expression evaluated by qPCR in colon cancer cell lines u
FABP1/FAS in CaCo2, SW480, HTC116 and HT-29 cells upon rosiglitazone treatment at con
bars correspond to vehicle treated cells, clear gray bars correspond to rosiglitazone treatedof 20 μM for 24 h. We observed that β-catenin and PPARγ co-
immunoprecipitated, whereas no band was observed when Sox9 IP
was performed (Fig. 8). Immunoprecipitation experiments evidenced
a direct interaction between β-catenin and PPARγ but not for SOX9
protein.
3.6. Effect of SOX9 changes on viability and proliferation of colon cancer
cell lines
To assess the effect of SOX9 changes induced by PPARγ activation
on viability and proliferation of human colon cancer cell lines, wepon rosiglitazone treatment. mRNA expression analysis by qPCR of SOX9, CTNNB1 and
centration of 20 μM for 24 h. *, P b 0.05 value; **, P b 0.01; ***, P b 0.001. Dark gray
cells.
Fig. 5. Immunoﬂuorescence of SOX9 in colon cancer cell lines treated with rosiglitazone. Panels (a) show colon cancer cell lines before treatment stained with anti SOX9 antibody.
Panels (e) diplay SOX9 staining in colon cancer cell lines upon treatment with rosiglitazone. Nuclei were counterstained with 4′,6′-diamidino-2-phenylindole (blue) (Panels b and f).
Fig. 6. Immunoﬂuorescence of β-catenin in colon cancer cell lines treated with rosiglitazone. Panels (a) show colon cancer cell lines before treatment stained with anti β-Catenin
antibody. Panels (d) diplay β-catenin staining in colon cancer cell lines upon treatment with rosiglitazone. Nuclei were counterstained with 4′,6′-diamidino-2-phenylindole (blue)
(Panels b and e).
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Fig. 7. Immunoﬂuorescence of PPARγ in colon cancer cell lines treated with rosiglitazone. Panels (a) show colon cancer cell lines before treatment stained with anti PPARγ
antibody. Panels (c) diplay PPARγ staining in colon cancer cell lines upon treatment with rosiglitazone. Nuclei were counterstained with 4′,6′-diamidino-2-phenylindole (blue)
(Panels b and d).
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HCT116, and HT29 cell lines were assessed after incubation with
20 μM of rosiglitazone at 24, 48, 72, and 96 h. Rosiglitazone treatment
reduced HT-29 cells viability up to 20% at 72 h (p = 0.225) and up to
80% at 96 h (p = 0.027), respectively. Viability of the other three cell
lines showed a downward trend at 96 h (Fig. 9, Panel A).Fig. 8. Immunoprecipitation of β-catenin, PPARγ and SOX9 in colon cancer cell lines upon ros
(v = vehicle) or with 20 μM of rosiglitazone (Ros) for 24 h and total cellular proteins were
PPARγ and SOX9 in the immunoprecipitated fractions was analyzed by immunoblotting (IB)
using control IgG on cell extract. WL: whole lysate.The inhibitory effect on proliferation was evaluated on the cell
lines treated with increasing concentrations (10, 20, 40 and 60 μM)
of rosiglitazone for 48 h. After 48 hour incubation statistically signif-
icant dose dependent changes were observed in CaCo2 and HT-29 cell
lines (Fig. 9, Panel B). The optical density (OD) values of rosiglitazone
treated (20 μM, 40 μM, and 60 μM) groups were decreased in aiglitazone treatment. Sw480, CaCo2, HT-29 and HCT116 cells were treated with ethanol
immunoprecipitated (IP) with an anti-β-catenin antibody. The presence of β-catenin,
. All experiments were repeated at least two times. The negative control was performed
Fig. 9. MTT proliferation assay. Panel A: MTT viability assay of CaCo2, SW480, HTC116
and HT-29 control cells or cells treated with rosiglitazone at concentration of 20 μM at
24, 48, 72 and 96 h. Panel B: Inhibitory effect on proliferation was evaluated on the cell
lines treated with increasing concentrations (10, 20, 40 and 60 μM) of rosiglitazone for
48 h. *, P b 0.05 value; **, P b 0.01; ***, P b 0.001.
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(p b 0.01 and p b 0.001, respectively) (Fig. 9, Panel B). The inhibitory
effect evidenced on proliferation of SW480 and HCT116 cells was sig-
niﬁcantly lower with respect to CaCo2 and HT-29 cells.
3.7. Cell cycle analysis
We examined the effect of PPARγ activation on cell-cycle progres-
sion by means of rosiglitazone treatment in the four colon cancer
cell lines. As shown in Fig. 10, CaCo2 cells treated with 20 μM of
rosiglitazone for 24 h revealed an increase in the number of cells in
the G0/G1 phase and reduction in the number of cells in the S phase
when compared with the untreated cells. Furthermore, HT-29 cells
treated with 20 μM of rosiglitazone revealed a slight increase in the
number of cells in the G0/G1 phase and a reduction in the number
of cells in the S phase at 24 h when compared with the untreated
cells, although these effects were more evident at 48 h. No change
was observed for SW480 and HCT116 cell lines.
4. Discussion
SOX9 is a target gene of WNT/β-catenin pathway and PPARγ activa-
tion causes a decrease in β-catenin expression in normal intestinal mu-
cosa in mice, probably controlling the levels of known regulators of
β-catenin, such as APC, axin and GSK-3β [34]. In this study we have
evaluated SOX9, CTNNB1 and PPARG expression levels in CRC specimens,
and we have put in evidence SOX9 and CTNNB1 up-regulation and
PPARG down-regulation, an association with MSI and female gender,
but no differences in the survival curves were observed.
Our results are in agreement with previous ﬁnding of SOX9
overexpression reported in different papers [11,12], but not with the
clinical–pathological correlations and survival rates referred by other
authors [35,36]. Anyway, data reported in CRC patients by these authors
seem contrasting, considering that high SOX9 expression levels in thetumor tissue were found associated on the one handwith better surviv-
al rates [35] and on the other handwith advanced tumor stage, typically
causing poorer survival [36]. Besides, higher tumor tissue levels of SOX9
were found in patients 62 years of age or younger, and higher tumor tis-
sue levels of either PPARG and SOX9 expression were found in female
CRC patients. These associationsmight be correlated to the age and gen-
der related differences in CRC incidence and prognosis reported in epi-
demiological studies [40–42], and should be interpreted in relationship
to the molecular pathways modulated by female hormones. In particu-
lar, estrogens have been found to inﬂuence PPARγ expression in a tissue
speciﬁc-manner [43,44] and to determine SOX9 subcellular localization
[45].
Few studies report gender-related differences of PPARγ expres-
sion. No signiﬁcant gender-related differences were detected in the
tissue distribution of PPARγ subtypes in the zebraﬁsh [46], whereas
a gender-related difference in PPARγ expression with up-regulation
in female animals was evidenced in rat adipose tissues depending
on the levels of the sex hormones [47], and in bladder smooth muscle
of female Ossabaw swines, a porcine model of the metabolic syn-
drome [48]. In humans, gender-related differences of PPARγ ex-
pression have been evidenced in relationship to particular single
nucleotide polymorphisms [49], in para-physiological processes,
such as aging [50], and in frank pathological conditions, such as coro-
nary artery disease [51] or diabetes mellitus [52]. Besides, SOX9 is an
important transcription factor required for development and male
sex determination, which regulates the expression of target genes in
the associated pathways and is involved in the expansion and differ-
entiation of multiple cell lineages. Regarding the relationship be-
tween SOX9 expression levels and gender in neoplastic disease, it
has been evaluated in different types of human cancer, such as hepa-
tocellular carcinoma, gastric cancer, malignant glioma, lung cancer,
but no signiﬁcant association between SOX9mRNA levels and gender
was reported [53–57].
As reported above, high levels of SOX9 expression in tumor tissue
are strongly correlated with MSI in our CRC patients. Aggressiveness
of colorectal tumors is negatively associated with the phenomenon
of hypermutation related to altered DNA repair mechanisms and the
consequent exceeding rate of genetic mutation, and approximately
15–20% of CRC are hypermutated with 75% of them presenting MSI.
Whole-exome sequencing and integrative analysis of genomic data
have put in evidence that 93% of non-hypermutated and 97% of
hypermutated CRCs have a deregulated WNT signalling pathway
and SOX9 is one of the genes most frequently mutated [58].
MSI and CIN mutational pathways are involved in CRC progres-
sion, and MSI inﬂuences response to irinotecan versus 5-FU chemo-
therapy [37,3] and conditionates cancer speciﬁc survival [38,39].
SOX9 expression was evaluated in MSS and MSI CRC by comparing
transcript proﬁles of normal mucosa and CRC tissue in two indepen-
dent sample sets, and different expression of this transcription factor
was found. It is important to consider that analysis was performed
through gene expression proﬁle by microarray to evaluate transcrip-
tion factors putatively associated with recurrence of stage II MSS
andMSI CRC [59]. On the other hand, we did not ﬁnd a signiﬁcant cor-
relation for CTNNB1. Anyway, our data show a trend (CTNNB1 expres-
sion decreased in MSI-H in respect to MSI-l and MSS) that is in
agreement with data evidenced in articles that investigated the
relationship between CTNNB1 mutations and underlying pathways
of genomic instability: the frequency of β-catenin mutations was sig-
niﬁcantly higher, and presumably CTNNB1 expression levels lower, in
MSI-H than in MSS/MSI-L CRC [60,61].
Besides, Kaplan and Meyer analysis in our study showed no corre-
lation of PPARG, SOX9 and CTNNB1 expression levels with patient sur-
vival. As reported by Ogino et al. [26], two studies, one considering 86
CRC patients and one considering 99 CRC patients, did not show a
prognostic value of tumoral PPARG expression, and he found statisti-
cally signiﬁcant differences only in a very large cohort (470) of CRC
Fig. 10. Effect of SOX9 decrease following PPARγ activation on cell-cycle. Cell-cycle proﬁle was examined by ﬂow cytometry and percentages of cells in G0/G1, S, and G2/M phase in
CaCo2, HT-29, HTC116 and SW480 cell lines are indicated in the graphs.
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signiﬁcant difference in overall survival (p = 0.0047), and a not sta-
tistically signiﬁcant difference in colorectal cancer speciﬁc survival
(p = 0.089) after 10 years of follow-up. These results suggest that a
very long follow-up and a very large sample size are necessary to
put in evidence an effect of these transcription factors on survival,
maybe in relationship to pleiotropic effects and inﬂuence of genetic
background.
In this instance, our study was meant to focus on biomolecular in-
teractions and subcellular localizations of SOX9, β-catenin and PPARγ
in different colon cancer cell lines.
To assess if SOX9 and β-catenin expression was inﬂuenced by
PPARγ activity we used CaCo2, SW480, HCT116, and HT29 colon can-
cer cell lines. We found that in some but not all the types of colon
cancer cell line examined PPARγ activation reduced SOX9 and
CTNNB1 gene expression levels. In particular, the modulation with
the PPARγ-agonist rosiglitazone induced a statistically signiﬁcant de-
crease of SOX9 and CTNNB1 expression in CaCo2 and in HT-29 celllines, a paradoxical signiﬁcant increase of SOX9 expression in
HCT116 cell line, and no signiﬁcant expression change in SW480 cells.
In a similar way, immunoﬂuorescence detection of SOX9 and
β-catenin in colon cancer cell lines evidenced contrasting patterns
of subcellular protein localization upon rosiglitazone treatment. The
subcellular localizations of β-catenin at the level of the membrane,
cytoplasm and nucleus affect its functions as a tumor suppressor at
the membrane or as an oncogene in the nucleus.
The different patterns of SOX9 and CTNNB1gene expression and
subcellular protein localization evidenced in the colon cancer cell
lines examined in our study might be related to different mutational
statuses for APC and/or β-catenin. Moreover, the shuttling between
the cytosol and the nucleus may occur through the direct interaction
of PPARγ with β-catenin, as evidenced in our IP experiment and al-
ready demonstrated [31,32]. On the contrary, our IP experiments
did not evidence a direct interaction between PPARγ/β-catenin and
SOX9 proteins, so that an indirect effect of PPARγ on SOX9 transcrip-
tion factor could be supposed.
1863A. Panza et al. / Biochimica et Biophysica Acta 1833 (2013) 1853–1865The CaCo2 cell line has both somatic CTNNB1 mutation (missense
variant at codon 245) and APC mutation (truncation at position
1367). The CTNNB1mutation is located in an amino acid that is direct-
ly N-terminal to a serine residue that lies in a consensus site for CK,
and might cause a potential change in the accessibility of that site
for phosphorylation [62]. Furthermore, PPARγ activation controls
the levels of β-catenin regulators, such as GSK-3β (crucial for phos-
phorylation), and has been found able to decrease β-catenin expres-
sion in normal intestinal mucosa in mice [30]. Another possible
mechanism may be represented by the direct interaction between
PPARγ and β-catenin with subsequent inhibition of β-catenin trans-
location into the nucleus [32]. The mutation in APC stabilizes
β-catenin constitutively activating Wnt-target genes [63]. According-
ly, in our study untreated CaCo2 cells displayed β-catenin localization
within nuclei, whereas upon 24-hour treatment with rosiglitazone
β-catenin protein was not present within the nuclei. Regarding to
SOX9 staining, untreated CaCo2 cells displayed nuclear localization,
which was slightly decreased in cells treated with rosiglitazone, prob-
ably in relationship to the absence of β-catenin nuclear localization.
SW480 are characterized only by a biallelic somatic APC mutation
(truncation at position 1338) that does not hamper β-catenin phos-
phorylation, but is not able to promote degradation, determining
high pβ-catenin levels [7,64]. We evidenced that untreated SW480
cells displayed membrane-bound β-catenin localization, and upon
24-hour treatment with rosiglitazone β-catenin was present within
the nuclei, suggesting delocalization from the plasma membrane to
the cytoplasm and transport into the nucleus. Regarding to a possible
mechanism involved in β-catenin nuclear translocation upon
rosiglitazone treatment, we can speculate on the molecular basis rely-
ing on previous data reported in the scientiﬁc literature. SW480 cells
build up high amounts of β-catenin (only 20% phosphorylated) that
might saturate the degradation machinery [64], and PPARγ activation
upon rosiglitazone treatment has been found capable of blocking the
phosphorylation of β-catenin suggesting that dephosphorylation
might be an alternative pathway that can protect β-catenin and in-
duce its nuclear accumulation [31]. In basal condition SW480 cell
are characterized by low PPARγ levels, so that rosiglitazone treat-
ment, by increasing the levels of the nuclear receptor, might subse-
quently facilitate β-catenin nuclear translocation. Concerning to
SOX9 staining, both untreated and rosiglitazone treated SW480 cells
displayed nuclear localization.
In HCT 116 cell line CTNNB1 heterozygous mutation (deletion of
codon 45) results in loss of highly conserved serine residues in a re-
gion of the protein that may be a target for the enzyme GSK-3β; the
phosphorylated (p) β-catenin may be derived from the wild-type
molecule generated from the intact allele and the proteolytic complex
formation is not disrupted. Indeed, no change was observed in the
HCT116 cell line for both proteins before and after rosiglitazone treat-
ment, with membrane-bound localization of β-catenin and nuclear
localization of SOX9.
HT-29 cells have a mutant form of the APC gene (truncation at po-
sition 1555) that can support some β-catenin phosphorylation, and is
at least partially capable of supporting its degradation [64]. Recently a
PPARγ region has been identiﬁed as having high homology to the
β-catenin binding domain (CBD) within TCF/LEF, which facilitates
its interaction with β-catenin [65]. In HT-29 cells PPARγ activation
has been found able to suppress β-catenin/TCF dependent transcrip-
tion via direct binding, which prevents its degradation and inhibits
β-catenin movement into the nucleus [32]. The subcellular distribu-
tion of the β-catenin destruction complex is mostly cytoplasmic and
the transient localization of β-catenin in junctions may reﬂect a com-
partmentalized shelter from degradation [64]. In untreated HT-29
cells we observed membrane-bound β-catenin localization, with an
increase in cell-cell junction localization upon 24-hour rosiglitazone
treatment. SOX9 staining displayed nuclear localization in untreated
and treated cells.The different patterns of response to rosiglitazone treatment thatwe
observed in the colon cancer cell lines examined mirror the conﬂicting
role played by PPARγ in gastrointestinal cancerogenesis, as this nuclear
receptor inhibits tumor growth only in the presence of functional APC
[30]. Accordingly, a tumor-promoting effect of PPARγ agonists has
been evidenced in the ApcMin/+ mice [66], implying that the normal re-
sponse of intestinal epithelial tumor cells to PPARγ agonists may be
modiﬁed by APC loss or dysfunction. The expression and subcellular lo-
calization data for PPARγ, SOX9 and β-catenin that we obtained by IF
and IP suggest a reciprocal interactions among these transcription fac-
tors, considering also that PPARγ lessens β-catenin levels upon ligand
related activation in the presence of a normal APC pathway [30], and
SOX9 is transcriptionally repressed by WNT signaling, while in turn
the SOX9 protein enhances β-catenin degradation [7,8,36]. Our data
suggest that the effect of rosiglitazone treatment on expression and traf-
ﬁcking of these transcription factors, and ultimately on cell viability and
proliferation rate, might be inﬂuenced by SOX9 and β-catenin levels,
that are decreased in CaCo2 an HT29 cells, and nuclear localization of
SOX9, decreased in CaCo2 cells, and β-catenin, absent in CaCo2 and
HT29, but increased in SW480 cells. In HCT116 cellsβ-catenin is not vis-
ible in the nucleus, but the paradoxical increase of SOX9 upon
rosiglitazone treatment might boost cell proliferation. SOX9 exhibits
several pro-oncogenic properties directly binding and activating the
promoter of the polycomb Bmi1, an oncogene playing an essential role
in proliferation, senescence and carcinogenesis, whose upregulation re-
presses the tumor suppressor Ink4a/Arf locus [36]. Besides, expression
of SOX9 matches cytoplasmic and nuclear β-catenin, corroborating the
link between SOX9 expression and the β-catenin/TCF complex activity
[7]. Otherwise, PPARγ could hinder SOX9 nuclear translocation and
maintain it in the cytosol, acting the same way as on β-catenin [32],
holding back the transcription processes inﬂuenced by SOX9.
Furthermore, in HCT116 cells we observed a statistically signiﬁ-
cant increase of SOX9 expression upon rosiglitazone treatment.
In these cells the M3 promoter region of PPARG is hypermethylated,
indicating that extensive promotermethylation inﬂuences PPARγ activ-
ity [25]. Besides, HCT116 cells are characterized by elevated PPARδ ex-
pression and are resistant to PPARγ agonists, because PPARδ activity
antagonizes the ability of PPARγ to induce its effects [67]. PPARδ is in-
volved in the Wnt/β-catenin signaling pathway interacting with
β-catenin binding to TCF/LEF transcription factors and inﬂuences also
SOX9 expression [68,69]. These evidences have important drawbacks,
considering that SOX9 overexpression is associated with an adverse
prognosis in colorectal cancer [35].
Furthermore, using MTT assay we have explored the effects on cell
proliferation of the decrease of SOX9 and CTNNB1 expression induced
by PPARγ activation after rosiglitazone treatment of the colon cancer
cell lines examined. Time and dose dependent signiﬁcant changes
after rosiglitazone treatment were evidenced only for CaCo2 and
HT-29 cell lines. This evidence is corroborated by cell-cycle progression
study performed by ﬂuorescence-activated cell-sorting analysis. In
CaCo2, and HT-29 cells treated with rosiglitazone an increase in the
number of cells in the G0/G1 phase and a reduction in the number of
cells in the S phase were evidencedwhen comparedwith the untreated
cells. Our results are in agreement with the regulation of proliferation
by SOX9 previously reported in primary cells through control of the
progression of the cell cycle from the G0/G1 to the S phase [35]. More-
over, we evaluated the basal expression levels of PPARG in the different
colon cancer cell lines, andwe found very high levels in HT29 cells, high
levels in HCT116 cells, and very low levels in SW480 cells, normalizing
to PPARG expression level in CaCo2 cells (see Supplementary Fig. 1S).
The level of PPARG expression evidenced in the colon cancer cell lines
examined is in agreement with the PPARγ protein level reported in a
seminal study [70]. The effects of PPARγ activation depend on cell con-
text and set inmotion downstream gene activation events directing cell
fate, and including decreases in proliferation through either cyclins or
cyclin-dependent kinases, cell differentiation through up-regulation of
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apoptosis-associated proteins, and growth arrest through overcoming
the effects of RAS/MEK/MAP kinase pathway derangement [70]. Fur-
thermore, the role of PPARγ might depend on a direct interaction
with β-catenin, considering that upon ligand-dependent activation
PPARγ keeps β-catenin in the cytosol and decreases β-catenin/TCF
complex, restraining β-catenin-mediated transcriptional pathways
that uphold cell proliferation [32].
Considering that in HCT116 cells promoter hypermethylation
modulates PPARG activity and that an effect of rosiglitazone treatment
on proliferation and cell cycle is evident only in HT29 and CaCo2 cells,
changes in these cell processes seem to be dependent on high basal
levels of this transcription factor. In agreement with the literature,
the results of our study suggest that basal levels of PPARG expression
inﬂuence the percentages of cells distributed in the different stages of
the cell cycle. Higher percentages of cells in G0/G1 and lower percent-
ages of cells in the G2/M phase were found in HT29 and HCT116 cells,
which express higher levels of PPARG, whereas the lowest percentage
of cells in G0/G1 and highest percentage of cells in the G2/M phase
were found in the SW480 cell line, which is characterized by very
low levels of PPARG expression. The CaCo2 cell line showed interme-
diate values of PPARG expression when compared to the other cell
lines examined, and basal percentages of distribution of cells in differ-
ent stages of the cell cycle were similar to those found in SW480 cells.
However, upon rosiglitazone treatment the former cell line showed
percentage changes with increase of cells in the G0/G1 phase, corre-
sponding to the disappearance of β-catenin nuclear localization, dif-
ferently from the latter cell line that did not display modiﬁcations of
distribution of cells in different stages of the cell cycle, but showed
de novo β-catenin nuclear localization after PPARγ activation.
In conclusion the expression of SOX9, β-catenin and PPARγwhich is
deregulated in colorectal cancer tissue and the modiﬁed levels of SOX9
and β-catenin evidenced in some colon cancer cell line after PPARγ ac-
tivation suggest a novel gene regulatory interaction in colorectal carci-
nogenesis. Our results shed light on a possible mechanism through
which PPARγ ligand-dependent activationmay affect tumor cell pheno-
type and behavior, as well as cell viability and proliferation. SOX9
upregulation and β-catenin delocalization are predictive markers of ag-
gressive biological behavior and our study suggests that PPARγ activa-
tion may inﬂuence SOX9 and β-catenin expression and subcellular
localization, at least in some types of colon cancer cell. A better under-
standing of these molecular mechanisms may further disclose the role
played by SOX9 and β-catenin and clarify the contrasting effects of
PPARγ transcriptional activation on tumorigenesis, testing the feasibil-
ity of drug modulation of their gene expression and translating these
discoveries into clinical use of new therapeutic targets.
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